Cash position at 31 December 2020: â¬10.6 million Cash runway to end of 2021 PRIMAvera European pivotal study of Prima System initiated in Q4 2020 Paris, 19 February 2021 â 7.00 a.m. CET - Pixium Vision (FR0011950641 - PIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces its financial results for 2020. The 2020 financial statements were approved by Pixium Vision s Board of Directors at its meeting on 18 February 2021.
Lloyd Diamond, CEO of Pixium Vision commented We continued in 2020 to deliver on our plan of transitioning Pixium Vision from a research project to a commercially oriented company. We progressed our innovative Prima System to the last step of clinical development in Europe by initiating the PRIMAvera pivotal study and strengthened our presence in the US in anticipation of increasing clinical development in this key market. We are well positio
acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.
Virtual ‘Saturday Morning at the Zoo’
The nonprofit Wild Wonders animal refuge offers a virtual program, “Saturday Morning at The Zoo,” at 10 a.m. Saturday. The program features “The Rain Forest with animal ambassadors from the top of the canopy to the leafy covered floor of the forest.” Cost of the 45-minute Zoom session is $20. Registration closes at noon Friday at wildwonders.org.
CARLSBAD
Free series of Hebrew classes offered
A free series of Hebrew classes hosted by Congregation B’nai Tikvah will be held this month and in March for Hebrew readers who are ready for a comprehensive review. Level 2 for review and intermediate readers will begin in March for four sessions and will cover topics about the Passover Haggadah. The class along with books, materials and Internet support are covered by a national grant, “Read Hebrew Across America” by the National Jewish Outreach Program. This program is open to the North County community. Call (858) 472-0303 or email
Maculus Therapeutix welcomes Privity FZ LLE and Prepares Capital Raise for Novel Drug Delivery Platform
SANTA CLARA, CA & DUBAI, Feb 17, 2021 - (ACN Newswire) - Maculus Therapeutix, a preclinical-stage biopharmaceutical company which has developed a SINGLE injection delivery platform for diseases such as wet AMD (Age-related Macular Degeneration) and DME (Diabetic Macular Edema) instead of the standard 8-12 monthly injections, is pleased to welcome Privity FZ LLE as a partner and advisor for upcoming fundraising activities. Maculus plans to raise USD3 million with a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies.